Alberto Bardelli
Born in Turin in 1967, Alberto Bardelli graduated in Biological Sciences in 1991 at the University of the same city and then took a PhD in Biochemistry and Molecular Biology at University College London in the UK. From 1999 to 2004, he specialised in cancer genomics with luminary Bert Vogelstein at the Johns Hopkins University School of Medicine at the Howard Hughes Medical Institute in Baltimore. In 2004, he returned to Italy as director of a research unit dedicated to the study of cancer genomes at the Candiolo Tumour Institute and the Department of Oncology at the University of Turin, where he has been full professor of Histology since 2016. The work of his research group is focused on the development of precision medicine for cancer patients. His discoveries have defined a new diagnostic methodology, called liquid biopsy, which by means of a blood sample, using circulating tumour DNA, makes it possible to monitor the response to therapies and the effectiveness of surgery in colorectal cancer patients. These discoveries are at the basis of international clinical trials such as PEGASUS and CHRONOS. His findings have been published in over 200 scientific articles - including 100 as coordinator - in international journals such as Nature, Science, Cancer Cell, NatureMedicine, JAMA and Lancet Oncology. His H index, a measure of the citations received by his articles, is 98 and, as of 2014, he has been listed by Web of Science as one of the world's most cited researchers. He has been a member of national and international scientific associations such as the European Academy of Cancer Sciences since 2015 and the European Molecular Biology Organisation (EMBO) since 2017, was President of the European Association for Cancer Research (EACR) from 2018 to 2020, and is a member of the AIRC Foundation Scientific Committee for Cancer Research.
